Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan

Published:2019-02-20 Issue:6 Volume:54 Page:558-570
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Kobayashi Masahiro,Kudo Masatoshi,Izumi Namiki,Kaneko Shuichi,Azuma Mie,Copher Ronda,Meier Genevieve,Pan Janice,Ishii Mika,Ikeda Shunya

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/article/10.1007/s00535-019-01554-0/fulltext.html

Reference32 articles.

1. Balogh J, Victor D 3rd, Asham EH, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41–53.

2. European Association for The Study of The Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.

3. Kim MN, Kim BK, Han K-H. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia–Pacific region. J Gastroenterol. 2013;48:681–8.

4. Chiba T, Matsuzaki Y, Abei M, et al. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol. 1996;31:552–8.

5. Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology. 1993;18:47–53.

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic Therapies for Hepatocellular Carcinoma in India;Journal of Clinical and Experimental Hepatology;2024-11

2. Cost-effectiveness of immune checkpoint inhibitors as a first-line therapy for advanced hepatocellular carcinoma: a systematic review;Health Economics Review;2024-07-05

3. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update;Journal of Clinical Oncology;2024-05-20

4. Lenvatinib plus pembrolizumab in the patients with advanced previously treated endometrial cancer: A cost‐effectiveness analysis in the United States and in China;Journal of Obstetrics and Gynaecology Research;2024-03-14

5. Cost-effectiveness analysis: The missing factor in the management of HCC;Clinical Liver Disease;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3